| Dr David Candelaria, MD | |
|
280 Maple St, Ashland, OR 97520-1552 | |
| (541) 201-4000 | |
| Not Available |
| Full Name | Dr David Candelaria |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 35 Years |
| Location | 280 Maple St, Ashland, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1033112271 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD17629 (Oregon) | Primary |
| 207Q00000X | Family Medicine | 31332 (Colorado) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lower Umpqua Hospital District | Reedsport, OR | Hospital |
| Asante Ashland Community Hospital | Ashland, OR | Hospital |
| Entity Name | Josephine County |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295737336 PECOS PAC ID: 0941193957 Enrollment ID: O20040204000415 |
News Archive
The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD).
Putting brass where your money is could be a guarantee of safety according to researchers looking at the dangers of eating raw fish and shellfish in seafood restaurants, scientists heard today (Wednesday 10 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.
Most tumors contain regions of low oxygen concentration where cancer therapies based on the action of reactive oxygen species are ineffective.
Researchers at the University of Pittsburgh School of Medicine have identified two new classes of RNAs that are closely associated with a protein known to be a prognostic biomarker for breast cancer and could play a role in progression of prostate cancer.
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.
› Verified 1 days ago
| Entity Name | Lower Umpqua Hospital District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003874819 PECOS PAC ID: 6800703562 Enrollment ID: O20040212000228 |
News Archive
The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD).
Putting brass where your money is could be a guarantee of safety according to researchers looking at the dangers of eating raw fish and shellfish in seafood restaurants, scientists heard today (Wednesday 10 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.
Most tumors contain regions of low oxygen concentration where cancer therapies based on the action of reactive oxygen species are ineffective.
Researchers at the University of Pittsburgh School of Medicine have identified two new classes of RNAs that are closely associated with a protein known to be a prognostic biomarker for breast cancer and could play a role in progression of prostate cancer.
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.
› Verified 1 days ago
| Entity Name | Asante Physician Partners |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922381326 PECOS PAC ID: 8325206246 Enrollment ID: O20120223000671 |
News Archive
The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD).
Putting brass where your money is could be a guarantee of safety according to researchers looking at the dangers of eating raw fish and shellfish in seafood restaurants, scientists heard today (Wednesday 10 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.
Most tumors contain regions of low oxygen concentration where cancer therapies based on the action of reactive oxygen species are ineffective.
Researchers at the University of Pittsburgh School of Medicine have identified two new classes of RNAs that are closely associated with a protein known to be a prognostic biomarker for breast cancer and could play a role in progression of prostate cancer.
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr David Candelaria, MD Po Box 490, Grants Pass, OR 97528-0041 Ph: (541) 955-4655 | Dr David Candelaria, MD 280 Maple St, Ashland, OR 97520-1552 Ph: (541) 201-4000 |
News Archive
The U.S. Food and Drug Administration today approved Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD).
Putting brass where your money is could be a guarantee of safety according to researchers looking at the dangers of eating raw fish and shellfish in seafood restaurants, scientists heard today (Wednesday 10 September 2008) at the Society for General Microbiology's Autumn meeting being held this week at Trinity College, Dublin.
Most tumors contain regions of low oxygen concentration where cancer therapies based on the action of reactive oxygen species are ineffective.
Researchers at the University of Pittsburgh School of Medicine have identified two new classes of RNAs that are closely associated with a protein known to be a prognostic biomarker for breast cancer and could play a role in progression of prostate cancer.
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes.
› Verified 1 days ago
Dr. Jerome Stanford Nitzberg, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 273 Granite St, Ashland, OR 97520 Phone: 541-488-2130 | |
Anne Taylor, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 935 Siskiyou Blvd, Ashland, OR 97520 Phone: 541-482-2716 Fax: 541-488-5461 | |
Steven Wells, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 534 Washington St, Ashland, OR 97520 Phone: 541-203-0737 | |
Dr. Jenna Elizabeth Diggs, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 560 Catalina Dr, Ashland, OR 97520 Phone: 541-201-4800 | |
Dr. Rivka Ann Sanders, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 540 Catalina Dr, Ashland, OR 97520 Phone: 541-482-0061 Fax: 888-869-7645 | |
Daniel James Sengenberger, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 850 Siskiyou Blvd Ste 7, Ashland, OR 97520 Phone: 541-482-2920 |